0001415889-23-000689.txt : 20230109
0001415889-23-000689.hdr.sgml : 20230109
20230109165257
ACCESSION NUMBER: 0001415889-23-000689
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230105
FILED AS OF DATE: 20230109
DATE AS OF CHANGE: 20230109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klein Matthew B.
CENTRAL INDEX KEY: 0001808968
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35969
FILM NUMBER: 23518683
MAIL ADDRESS:
STREET 1: C/O PTC THERAPEUTICS, INC.
STREET 2: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001070081
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043416587
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
BUSINESS PHONE: 9082227000
MAIL ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
FORMER COMPANY:
FORMER CONFORMED NAME: PTC THERAPEUTICS INC
DATE OF NAME CHANGE: 19980909
4
1
form4-01092023_090149.xml
X0306
4
2023-01-05
0001070081
PTC THERAPEUTICS, INC.
PTCT
0001808968
Klein Matthew B.
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD
NJ
07080
false
true
false
false
CHIEF OPERATING OFFICER
Common Stock
2023-01-05
4
A
0
26000
0
A
83104
D
Stock Option (Right to Buy)
39.42
2023-01-05
4
A
0
65000
0
A
2033-01-04
Common Stock
65000
65000
D
Restricted stock units granted on January 5, 2023 that vest in four equal installments over four years, commencing on January 5, 2024.
Includes 263 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2022 and 277 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2022.
This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
/s/ Avraham S. Adler, Attorney-in-Fact
2023-01-09